Category

News Brief

This Geneticist’s Goal: Cure the Disease That Runs in His Family

Dr. Eric Wang has always been interested in understanding how biological systems function, but in part entered this field and joined the team at UF because he has family members affected by myotonic dystrophy. He is personally motivated to better understand DM and related diseases, and to find treatments.

Concept Companies and Lacerta Therapeutics Form a Strategic Partnership Around Facilities Expansion and Financing

Concept Companies, a national commercial real estate developer with a specialty across multiple asset classes including science and technology, and Lacerta Therapeutics, Inc., a leader in the AAV gene therapy space, today announced a strategic collaboration providing Lacerta with access to financing to support expansion of operations and new facilities. The financing is being provided via Agility Venture Capital, the funding arm of Concept Companies. 

Lacerta and Prevail, a Wholly Owned Subsidiary of Lilly, Sign Agreement To Develop Novel AAV Capsids for CNS Disorders

Lacerta Therapeutics, a leader in the development of adeno-associated virus (AAV) technologies for the treatment of central nervous system (CNS) diseases, announced a new AAV capsid licensing and research collaboration agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The collaboration will focus on the discovery and development of novel AAV capsids for CNS diseases.